<DOC>
	<DOCNO>NCT01492777</DOCNO>
	<brief_summary>The use oral anticoagulation mark elevate risk adverse drug event ( ADE ) due narrow therapeutic window lead important medical economical consequence . The risk ADE increase partly drug interaction recently identify genetic factor influence metabolism coumarins ( polymorphism cytochrome P450 CYP2C9 ) well target enzyme coumarins ( polymorphism vitamin K epoxide reductase complex subunit 1 ( VKORC1 ) . The objective determine impact several genotype acenocoumarol treatment vulnerability drug-drug interaction .</brief_summary>
	<brief_title>Pharmacogenetics Acenocoumarol</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Every patient require acenocoumarol therapy least 4 week target INR low intensity range ( INR range 23 ) Age â‰¥ 18 year Signed informed consent Severe cognitive impairment Previous current treatment coumarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>